THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [7.19] ID: TIP-MED-000121

Tapentadol Hydrochloride

Active Ingredient / Scientific Identity: Tapentadol Hydrochloride • Class: Centrally Acting Dual Mu-Opioid Receptor Agonist & Norepinephrine Reuptake Inhibitor (NRI) Analgesic (Schedule H1)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Tapentadol Hydrochloride ([7.19] | ID: TIP-MED-000121) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/7-19-tapentadol-hydrochloride/
Generic / Entity NameTapentadol Hydrochloride ([7.19])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassCentrally Acting Dual Mu-Opioid Receptor Agonist & Norepinephrine Reuptake Inhibitor (NRI)
Available Dosage FormsImmediate-Release (IR) Tablets: 50 mg, 75 mg, 100 mg; Extended-Release (ER) Tablets: 50 mg, 100 mg, 150 mg, 20
Regulatory ClassificationSchedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register un
Key Warning & Review DateRenal: No adjustment in mild-to-moderate CKD; CONTRAINDICATED in severe renal impairment (CrCl <30 mL/min). Hepatic: In moder
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H1 Prescription Drug (Mandatory Red-Bordere✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Tapentadol Hydrochloride (TIP-MED-000121, Reference Code [7.19]) is classified under Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Centrally Acting Dual Mu-Opioid Receptor Agonist & Norepinephrine Reuptake Inhibitor (NRI) Analgesic (Schedule H1). Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.19], p. 88): Tapal / Tapal ER (MSN), Tydol (Sun), Dolproxy, Tapenta (Zuventus) — Strengths & Dosage Forms: Immediate-Release (IR) Tablets: 50 mg, 75 mg, 100 mg; Extended-Release (ER) Tablets: 50 mg, 100 mg, 150 mg, 200 mg
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.19], p. 88): Tapal / Tapal ER (MSN), Tydol (Sun), Dolproxy, Tapenta (Zuventus) — Strengths & Dosage Forms: Immediate-Release (IR) Tablets: 50 mg, 75 mg, 100 mg; Extended-Release (ER) Tablets: 50 mg, 100 mg, 150 mg, 200 mg
Dosage Forms & Available Strengths:
Immediate-Release (IR) Tablets: 50 mg, 75 mg, 100 mg; Extended-Release (ER) Tablets: 50 mg, 100 mg, 150 mg, 200 mg
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Centrally Acting Dual Mu-Opioid Receptor Agonist & Norepinephrine Reuptake Inhibitor (NRI) Analgesic (Schedule H1) acting on target receptor/enzyme pathways in Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07): clinical efficacy is mediated via Centrally Acting Dual Mu-Opioid Receptor Agonist & Norepinephrine Reuptake Inhibitor (NRI) Analgesic (Schedule H1) for Moderate-to-severe acute pain (IR) and severe chronic musculoskeletal or diabetic neuropathic pain (ER) refractory to non-opioid analgesics (superior GI tolerability and zero CYP2D6 prodrug dependence compared with Tramadol).

4. Therapeutic Indications & Evidence-Supported Uses

  • Moderate-to-severe acute pain (IR) and severe chronic musculoskeletal or diabetic neuropathic pain (ER) refractory to non-opioid analgesics (superior GI tolerability and zero CYP2D6 prodrug dependence compared with Tramadol)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: IR (Acute Pain): 50–75 mg PO q6–8h PRN (Max 500–600 mg/day). ER (Chronic Pain): Start 50 mg ER PO BD (q12h), titrate to 100–200 mg ER BD (Max 500 mg/day)

Administration & Meal Timing: May be taken with or without food; swallow ER tablets WHOLE with water — NEVER crush, split, or chew ER tablets (dose-dumping causes fatal respiratory depression!) | Every 6–8h PRN (IR) or Morning & Evening q12h (ER)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: No adjustment in mild-to-moderate CKD; CONTRAINDICATED in severe renal impairment (CrCl <30 mL/min). Hepatic: In moderate hepatic impairment (Child–Pugh B), start at 50 mg no more than once every 24h; contraindicated in Child–Pugh C
Elimination & Renal Adjustment:
Renal: No adjustment in mild-to-moderate CKD; CONTRAINDICATED in severe renal impairment (CrCl <30 mL/min). Hepatic: In moderate hepatic impairment (Child–Pugh B), start at 50 mg no more than once every 24h; contraindicated in Child–Pugh C
Hepatic Impairment Considerations:
Renal: No adjustment in mild-to-moderate CKD; CONTRAINDICATED in severe renal impairment (CrCl <30 mL/min). Hepatic: In moderate hepatic impairment (Child–Pugh B), start at 50 mg no more than once every 24h; contraindicated in Child–Pugh C

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • SCHEDULE H1 / CONTROLLED OPIOID: Contraindicated in severe respiratory depression/acute asthma, paralytic ileus, acute intoxication with alcohol/hypnotics, and within 14 days of MAO inhibitors (Linezolid, Selegiline). Lowers seizure threshold!

Key Clinical Precautions: Renal: No adjustment in mild-to-moderate CKD; CONTRAINDICATED in severe renal impairment (CrCl <30 mL/min). Hepatic: In moderate hepatic impairment (Child–Pugh B), start at 50 mg no more than once every 24h; contraindicated in Child–Pugh C

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Nausea, dizziness, somnolence, headache, constipation (significantly lower nausea and constipation than equianalgesic Oxycodone/Morphine or Tramadol)
  • Respiratory depression, Serotonin Syndrome (when combined with SSRIs/SNRIs/MAOIs), seizures, physical dependence/withdrawal on abrupt cessation
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • CNS depressants (Benzodiazepines, Zolpidem, Alcohol, Gabapentinoids) cause additive fatal respiratory depression; SSRIs, SNRIs, TCAs, Triptans, and Linezolid increase Serotonin Syndrome & seizure risk
  • Metabolised primarily via Phase II UGT glucuronidation (minimal CYP450 DDIs!)

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Swallow ER tablets whole; causes drowsiness — do not drive or drink alcohol; record in pharmacy Schedule H1 register (3-year retention); taper gradually if taken for >1–2 weeks
  • Meal & Clock Timing Instruction: May be taken with or without food; swallow ER tablets WHOLE with water — NEVER crush, split, or chew ER tablets (dose-dumping causes fatal respiratory depression!) (Every 6–8h PRN (IR) or Morning & Evening q12h (ER))
  • Missed Dose Protocol: Take PRN (IR) or skip if close to next ER dose; never double dose
  • Geriatric Dispensing Pearl: Start at lowest dose (50 mg IR q8–12h) in older adults; monitor closely for sedation, falls, and constipation

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Immediate-Release (IR) Tablets: 50 mg, 75 mg, 100 mg; Extended-Release (ER) Tablets: 50 mg, 100 mg, 150 mg, 200 mg

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 07 [7.19] (p. 88)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/7-19-tapentadol-hydrochloride/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.